

Jean Donadieu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4542916/publications.pdf>

Version: 2024-02-01

128
papers

12,037
citations

29994

54
h-index

27345

106
g-index

134
all docs

134
docs citations

134
times ranked

10294
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterozygous variants of <i>CLPB</i> are a cause of severe congenital neutropenia. <i>Blood</i> , 2022, 139, 779-791.	0.6	25
2	ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. <i>Blood</i> , 2022, 139, 256-280.	0.6	60
3	Establishment of MOS-SF36 percentile ranks in the general youth French population. <i>BMC Psychology</i> , 2022, 10, 74.	0.9	2
4	Prognostic impact of pulmonary nodules diagnosed at initial presentation in patients with osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2022, , e29725.	0.8	1
5	Eye movement abnormalities in neurodegenerative langerhans cell histiocytosis. <i>Neurological Sciences</i> , 2022, 43, 6539-6546.	0.9	3
6	Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients. <i>European Journal of Cancer</i> , 2022, 172, 138-145.	1.3	15
7	Identification of biallelic germline variants of <i>SRP68</i> in a sporadic case with severe congenital neutropenia. <i>Haematologica</i> , 2021, 106, 1216-1219.	1.7	10
8	High frequency of clonal hematopoiesis in Erdheim-Chester disease. <i>Blood</i> , 2021, 137, 485-492.	0.6	30
9	Langerhans cell histiocytosis with extensive lung destruction: Not always the worst case scenario. <i>Pediatric Pulmonology</i> , 2021, 56, 327-328.	1.0	0
10	Inherited <i>GATA2</i> Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance. <i>Journal of Clinical Immunology</i> , 2021, 41, 639-657.	2.0	30
11	Long-term outcome of severe paediatric pulmonary Langerhans cell histiocytosis: do not underestimate lung plasticity. <i>BMJ Case Reports</i> , 2021, 14, e241860.	0.2	1
12	Shwachman-Diamond syndrome and solid tumors: Three new patients from the French Registry for Severe Chronic Neutropenia and literature review. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29071.	0.8	4
13	<i>CXCR4</i> signaling controls dendritic cell location and activation at steady state and in inflammation. <i>Blood</i> , 2021, 137, 2770-2784.	0.6	16
14	Cutaneous adverse events in children treated with vemurafenib for refractory <i>BRAF</i> ^{V600E} mutated Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29140.	0.8	6
15	A circulating subset of <i>BRAF</i> ^{V600E} -positive cells in infants with high-risk Langerhans cell histiocytosis treated with <i>BRAF</i> inhibitors. <i>British Journal of Haematology</i> , 2021, 194, 745-749.	1.2	5
16	Histiocytosis. <i>Lancet, The</i> , 2021, 398, 157-170.	6.3	58
17	Somatic genetic rescue of a germline ribosome assembly defect. <i>Nature Communications</i> , 2021, 12, 5044.	5.8	44
18	Recurrent bacterial infections, but not fungal infections, characterise patients with <i>ELANE</i> -related neutropenia: a French Severe Chronic Neutropenia Registry study. <i>British Journal of Haematology</i> , 2021, 194, 908-920.	1.2	11

#	ARTICLE	IF	CITATIONS
19	Chronic neutropenia: how best to assess severity and approach management?. Expert Review of Hematology, 2021, 14, 945-960.	1.0	6
20	Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis. Journal of Pediatrics, 2021, 237, 65-70.e3.	0.9	8
21	Post-COVID-19 severe neutropenia. Pediatric Blood and Cancer, 2021, 68, e28866.	0.8	9
22	EFL1 deficiency: a little is better than nothing. Blood, 2021, 138, 2016-2018.	0.6	0
23	Congenital and Acquired Chronic Neutropenias: Challenges, Perspectives and Implementation of the EuNet-INNOCHRON Action. HemaSphere, 2020, 4, e406.	1.2	2
24	Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment. British Journal of Haematology, 2020, 191, 825-834.	1.2	14
25	Chest computed tomography findings for a cohort of children with pulmonary Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2020, 67, e28496.	0.8	7
26	Central nervous system involvement in Erdheim-Chester disease. Neurology, 2020, 95, e2746-e2754.	1.5	22
27	Childhood Langerhans cell histiocytosis with severe lung involvement: a nationwide cohort study. Orphanet Journal of Rare Diseases, 2020, 15, 241.	1.2	14
28	Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review. British Journal of Haematology, 2020, 189, 869-878.	1.2	14
29	PTPN11 mutations in canine and human disseminated histiocytic sarcoma. International Journal of Cancer, 2020, 147, 1657-1665.	2.3	14
30	HSCT may lower leukemia risk in ELANE neutropenia: a before-after study from the French Severe Congenital Neutropenia Registry. Bone Marrow Transplantation, 2020, 55, 1614-1622.	1.3	24
31	Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort. Molecular Genetics and Metabolism Reports, 2020, 23, 100581.	0.4	12
32	How Many Patients Have Congenital Neutropenia? a Population-Based Estimation from the Nationwide French Severe Chronic Neutropenia Registry. Blood, 2020, 136, 40-41.	0.6	3
33	Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis. Case Reports in Endocrinology, 2019, 2019, 1-8.	0.2	1
34	Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. Journal of Clinical Oncology, 2019, 37, 2857-2865.	0.8	132
35	Atteintes ostéoarticulaires au cours des histiocytoses. Revue Du Rhumatisme Monographies, 2019, 86, 120-125.	0.0	0
36	Management of Gorham Stout disease with skull-base defects: Case series of six children and literature review. International Journal of Pediatric Otorhinolaryngology, 2019, 124, 152-156.	0.4	14

#	ARTICLE	IF	CITATIONS
37	EFL1 mutations impair eIF6 release to cause Shwachman-Diamond syndrome. <i>Blood</i> , 2019, 134, 277-290.	0.6	48
38	Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAFV600E mutation study from the French national cohort. <i>Human Pathology</i> , 2019, 89, 51-61.	1.1	14
39	Severe Transitory Neonatal Neutropenia Associated with Maternal Autoimmune or Idiopathic Neutropenia. <i>Journal of Clinical Immunology</i> , 2019, 39, 200-206.	2.0	3
40	Cladribine-related immunosuppression may have fostered graft-versus-host disease after lung transplant for pulmonary Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27477.	0.8	4
41	Highly sensitive methods are required to detect mutations in histiocytoses. <i>Haematologica</i> , 2019, 104, e97-e99.	1.7	27
42	Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. <i>American Journal of Hematology</i> , 2018, 93, E114-E117.	2.0	94
43	TP53 mutations: the dawn of Shwachman clones. <i>Blood</i> , 2018, 131, 376-377.	0.6	8
44	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. <i>Blood</i> , 2018, 131, 2877-2890.	0.6	335
45	Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. <i>British Journal of Haematology</i> , 2018, 183, 608-617.	1.2	54
46	Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome. <i>Blood</i> , 2018, 132, 1318-1331.	0.6	85
47	Distinctive vasculopathy with systemic involvement due to levamisole long-term therapy: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 209.	0.4	6
48	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. <i>Haematologica</i> , 2018, 103, 1278-1287.	1.7	129
49	Histiocytoses: emerging neoplasia behind inflammation. <i>Lancet Oncology</i> , The, 2017, 18, e113-e125.	5.1	154
50	Circulating cell-free BRAF ^{V600E} as a biomarker in children with Langerhans cell histiocytosis. <i>British Journal of Haematology</i> , 2017, 178, 457-467.	1.2	57
51	Lymphoid differentiation of hematopoietic stem cells requires efficient Cxcr4 desensitization. <i>Journal of Experimental Medicine</i> , 2017, 214, 2023-2040.	4.2	36
52	Neurodegeneration in histiocytoses might start in utero. <i>Lancet Neurology</i> , The, 2017, 16, 953-954.	4.9	2
53	Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history. <i>British Journal of Haematology</i> , 2017, 179, 557-574.	1.2	115
54	How to differentiate congenital from noncongenital chronic neutropenia at the first medical examination? Proposal of score: A pilot study from the French Severe Chronic Neutropenia registry. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26722.	0.8	17

#	ARTICLE	IF	CITATIONS
55	Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet Journal of Rare Diseases, 2017, 12, 95.	1.2	57
56	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood, 2017, 130, 1377-1380.	0.6	146
57	Application of whole-exome sequencing to unravel the molecular basis of undiagnosed syndromic congenital neutropenia with intellectual disability. American Journal of Medical Genetics, Part A, 2017, 173, 62-71.	0.7	23
58	New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Molecular Cancer, 2017, 16, 115.	7.9	37
59	<i>BRAF</i> Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. Journal of Clinical Oncology, 2016, 34, 3023-3030.	0.8	233
60	Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. British Journal of Haematology, 2016, 174, 887-898.	1.2	83
61	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood, 2016, 127, 2672-2681.	0.6	1,040
62	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	7.7	372
63	Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis. Blood, 2015, 125, 2448-2449.	0.6	28
64	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood, 2015, 126, 1885-1892.	0.6	76
65	Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood, 2015, 126, 1643-1650.	0.6	32
66	Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood, 2015, 126, 1415-1423.	0.6	117
67	Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With <i>BRAF</i> ^{V600E} -Mutated Erdheim-Chester Disease. Journal of Clinical Oncology, 2015, 33, 411-418.	0.8	238
68	Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. Journal of the American Academy of Dermatology, 2015, 73, e29-e30.	0.6	22
69	Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. JAMA Oncology, 2015, 1, 836.	3.4	92
70	Cladribine improves lung cysts and pulmonary function in a child with histiocytosis. European Respiratory Journal, 2015, 45, 831-833.	3.1	20
71	Early-onset hypogammaglobulinemia: A survey of 44 patients. Journal of Allergy and Clinical Immunology, 2015, 136, 1097-1099.e2.	1.5	5
72	Langerhans cell histiocytosis in children: Correlation of <i>BRAF</i> status with clinical characteristic.. Journal of Clinical Oncology, 2015, 33, 10003-10003.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French severe congenital neutropenia registry. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 183.	1.2	48
74	Dramatic response of a <i>BRAF</i> V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. <i>Neurology</i> , 2014, 83, 1478-1480.	1.5	70
75	Neurological findings and genetic alterations in patients with Kostmann syndrome and <i>HAX1</i> mutations. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1041-1048.	0.8	24
76	JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. <i>Nature Genetics</i> , 2014, 46, 1021-1027.	9.4	119
77	Prevention of Infections During Primary Immunodeficiency. <i>Clinical Infectious Diseases</i> , 2014, 59, 1462-1470.	2.9	81
78	The cognitive spectrum in neurodegenerative Langerhans cell histiocytosis. <i>Journal of Neurology</i> , 2014, 261, 1537-1543.	1.8	13
79	Cohen syndrome is associated with major glycosylation defects. <i>Human Molecular Genetics</i> , 2014, 23, 2391-2399.	1.4	79
80	Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. <i>Blood</i> , 2014, 123, 2229-2237.	0.6	135
81	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 3016-3019.	0.6	197
82	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. <i>Blood</i> , 2014, 124, 1119-1126.	0.6	208
83	Natural history of Barth syndrome: a national cohort study of 22 patients. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 70.	1.2	93
84	Epidemiology of Congenital Neutropenia. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1-17.	0.9	55
85	Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical workup, and treatment for patients till the age of 18 years. <i>Pediatric Blood and Cancer</i> , 2013, 60, 175-184.	0.8	496
86	Cardiomyopathies and congenital heart diseases in Shwachman-Diamond syndrome: A national survey. <i>International Journal of Cardiology</i> , 2013, 167, 1048-1050.	0.8	13
87	Thymus and mediastinal node involvement in childhood langerhans cell histiocytosis: Long-term follow-up from the French national cohort. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1759-1765.	0.8	35
88	High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. <i>Blood</i> , 2013, 121, 822-829.	0.6	189
89	Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. <i>Blood</i> , 2013, 121, 5006-5014.	0.6	343
90	Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. <i>Blood</i> , 2013, 121, 1495-1500.	0.6	479

#	ARTICLE	IF	CITATIONS
91	Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome. <i>Haematologica</i> , 2012, 97, 1312-1319.	1.7	120
92	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. <i>Blood</i> , 2012, 120, 2700-2703.	0.6	589
93	Tetralogy of Fallot is an Uncommon Manifestation of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome. <i>Journal of Pediatrics</i> , 2012, 161, 763-765.	0.9	37
94	B cell "helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. <i>Nature Immunology</i> , 2012, 13, 170-180.	7.0	615
95	Medical management of langerhans cell histiocytosis from diagnosis to treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1309-1322.	0.9	86
96	Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 71.	1.2	96
97	B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease. <i>PLoS ONE</i> , 2012, 7, e33891.	1.1	132
98	Neutrophil depletion impairs natural killer cell maturation, function, and homeostasis. <i>Journal of Experimental Medicine</i> , 2012, 209, 565-580.	4.2	199
99	Extended Spectrum of Human Glucose-6-Phosphatase Catalytic Subunit 3 Deficiency: Novel Genotypes and Phenotypic Variability in Severe Congenital Neutropenia. <i>Journal of Pediatrics</i> , 2012, 160, 679-683.e2.	0.9	67
100	Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. <i>Annals of the New York Academy of Sciences</i> , 2011, 1242, 40-55.	1.8	183
101	Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 83.	1.2	48
102	Congenital neutropenia: diagnosis, molecular bases and patient management. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 26.	1.2	173
103	Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome. <i>Genes and Development</i> , 2011, 25, 917-929.	2.7	247
104	Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. <i>Haematologica</i> , 2010, 95, 1534-1541.	1.7	176
105	Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1068-1073.	0.8	24
106	2-Deoxychlorodeoxyadenosine (2-CD) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-598 protocol of the histiocyte society. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1271-1276.	0.8	97
107	Cholesteatoma Secondary to Temporal Bone Involvement by Langerhans Cell Histiocytosis. <i>Otology and Neurotology</i> , 2009, 30, 190-193.	0.7	11
108	Respiratory distress and sudden death of a patient with GSD1b chronic neutropenia: possible role of pegfilgrastim. <i>Haematologica</i> , 2009, 94, 1175-1177.	1.7	13

#	ARTICLE	IF	CITATIONS
109	Neutropenia in congenital nephrotic syndrome of the Finnish type: role of urinary ceruloplasmin loss. <i>Blood</i> , 2009, 113, 4820-4821.	0.6	16
110	18F-FDG PET in neurodegenerative Langerhans cell histiocytosis. <i>Journal of Neurology</i> , 2008, 255, 575-580.	1.8	30
111	Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. <i>Pediatric Blood and Cancer</i> , 2008, 51, 71-75.	0.8	248
112	Reactivations in Multisystem Langerhans Cell Histiocytosis: Data of the International LCH Registry. <i>Journal of Pediatrics</i> , 2008, 153, 700-705.e2.	0.9	88
113	Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. <i>Blood</i> , 2008, 111, 2556-2562.	0.6	287
114	Herpes-Virus Infection in Patients with Langerhans Cell Histiocytosis: A Case-Controlled Sero-Epidemiological Study, and In Situ Analysis. <i>PLoS ONE</i> , 2008, 3, e3262.	1.1	48
115	Estimation of the Radiation Dose From Thoracic CT Scans in a Cystic Fibrosis Population. <i>Chest</i> , 2007, 132, 1233-1238.	0.4	46
116	Epigenetic Regulation of Protein-Coding and MicroRNA Genes by the Gfi1-Interacting Tumor Suppressor PRDM5. <i>Molecular and Cellular Biology</i> , 2007, 27, 6889-6902.	1.1	79
117	Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. <i>Blood</i> , 2007, 110, 1648-1655.	0.6	88
118	Is G-CSF-mobilized peripheral stem cell harvest harmful?. <i>Pediatric Blood and Cancer</i> , 2007, 48, 595-595.	0.8	3
119	The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report. <i>Supportive Cancer Therapy</i> , 2006, 3, 220-231.	0.3	135
120	Langerhans cell histiocytosis: a clinical update. , 2005, , 95-129.		30
121	Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. <i>Haematologica</i> , 2005, 90, 45-53.	1.7	234
122	Incidence of Growth Hormone Deficiency in Pediatric-Onset Langerhans Cell Histiocytosis: Efficacy and Safety of Growth Hormone Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 604-609.	1.8	95
123	A New clinical score for disease activity in Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2004, 43, 770-776.	0.8	82
124	Endocrine involvement in pediatric-onset langerhans' cell histiocytosis: a population-based study. <i>Journal of Pediatrics</i> , 2004, 144, 344-350.	0.9	181
125	Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. <i>Blood</i> , 2004, 103, 4119-4125.	0.6	187
126	Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. <i>Seminars in Hematology</i> , 2002, 39, 134-140.	1.8	54

#	ARTICLE	IF	CITATIONS
127	Langerhans Cell Histiocytosis and the Central Nervous System in Childhood: Evolution and Prognostic Factors. Results of a Collaborative Study. <i>Journal of Child Neurology</i> , 2000, 15, 150-156.	0.7	63
128	Renal Carcinoma in a Patient With Glycogen Storage Disease Ib Receiving Long-term Granulocyte Colony-Stimulating Factor Therapy. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2000, 22, 188-189.	1.3	12